Ligand Pharma Says FDA Approves Travere's FILSPARI For Focal Segmental Glomerulosclerosis

Travere Therapeutics received FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years. The decision is a meaningful regulatory win for Travere and a positive catalyst for partner Ligand Pharmaceuticals, supporting commercialization and revenue potential. The news is company-specific rather than sector-wide, but could lift shares on improved product outlook.

Analysis

Travere Therapeutics received FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years. The decision is a meaningful regulatory win for Travere and a positive catalyst for partner Ligand Pharmaceuticals, supporting commercialization and revenue potential. The news is company-specific rather than sector-wide, but could lift shares on improved product outlook.